Aridis Pharmaceuticals has raised $26m through an initial public offering of two million shares of its common stock priced at $13 a share.
The underwriters will have a 30-day option to buy an additional 0.3 million shares of the company’s common stock.
Based in the US, Aridis is a biopharmaceutical company focused on the development of innovative therapies for infectious diseases.
Xeris Pharmaceuticals has raised $98.3m through an initial public offering of 6.5 million shares of its common stock priced at $15 a share.
The underwriters will have a 30-day option to buy an additional 0.85 million shares of the company’s common stock.
Based in the US, Xeris is a speciality pharmaceutical company engaged in the development and commercialisation of room-temperature stable injectable and infusible drug formulations.
Quethera will receive £85m ($108.5m) in upfront and contingent payments from Astellas, as part of the transaction.
The acquisition includes Quethera’s ophthalmic gene therapy programme, which will be a complementary addition to Astellas’ portfolio.
Based in Japan, Astellas is a pharmaceutical company offering products for several therapeutic areas such as cardiology, dermatology, oncology, and urology.
The deal enables the acquirer company to accelerate the development of investigational technology programme to prevent disease progression in patients suffering from serious diseases.
The transaction includes US FDA licensed Vivotif vaccine indicated for the treatment of typhoid fever, and Vaxchora, a vaccine used for the prevention of cholera. In addition, the purchase includes the target company’s European biologics manufacturing.
Based in the US, Emergent BioSolutions is engaged in the development and commercialisation of immunobiotics such as vaccines and immune globulins, while PaxVax, also based in the US, is a manufacturer of vaccines for various infectious diseases.
The transaction will enable Emergent BioSolutions to diversify its customer base and international reach and boost its contract development and manufacturing capabilities.